Nitrogen Bonded Directly To The Metal Patents (Class 556/137)
-
Patent number: 8614345Abstract: The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of specific ruthenium catalysts, or pre-catalysts, in hydrogenation processes for the reduction of ketones and/or aldehydes into the corresponding alcohol respectively. Said catalysts are ruthenium complexes comprising a tetradentate ligand (L4) coordinating the ruthenium with: —two nitrogen atoms, each in the form of a primary or secondary amine (i.e. a NH2 or NH group) or N-alkyl imine functional groups (i.e. a C?N group), and —two sulfur atoms, each in the form of thioether functional groups.Type: GrantFiled: December 19, 2011Date of Patent: December 24, 2013Assignee: Firmenich SAInventors: Francesco Santoro, Lionel Saudan, Michel Alfred Joseph Saudan, Sylvia Joyeuse Adélaïde Ada Saudan
-
Publication number: 20130336969Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.Type: ApplicationFiled: March 2, 2011Publication date: December 19, 2013Applicant: INSTITUT DE CANCEROLOGIE DE L'OUESTInventors: Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
-
Patent number: 8609864Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.Type: GrantFiled: January 7, 2010Date of Patent: December 17, 2013Assignee: Purdue Pharmaceutical Products, L.P.Inventors: Yu Chen, Yi Chen
-
Publication number: 20130331566Abstract: Described are palladium precatalysts, and methods of making and using them. The palladium precatalysts show improved stability and improved reactivity in comparison to previously-described palladium precatalysts.Type: ApplicationFiled: March 13, 2013Publication date: December 12, 2013Applicant: Massachusetts Institute of TechnologyInventors: Nicholas C. Bruno, Stephen L. Buchwald
-
Patent number: 8597803Abstract: A light emitting composition includes a light-emitting lumophore-functionalized nanoparticle, such as an organic-inorganic light-emitting lumophore-functionalized nanoparticle. A light emitting device includes an anode, a cathode, and a layer containing such a light-emitting composition. In an embodiment, the light emitting device can emit white light.Type: GrantFiled: May 9, 2012Date of Patent: December 3, 2013Assignee: Nitto Denko CorporationInventors: Jesse Froehlich, Hyun Sik Chae, Amane Mochizuki, Sheng Li
-
Patent number: 8592617Abstract: The present application is generally directed to ruthenium or osmium containing complexes and their use as redox mediators in electrochemical biosensors.Type: GrantFiled: December 21, 2006Date of Patent: November 26, 2013Assignee: Roche Diagnostics Operations, Inc.Inventors: Hugh Oliver Allen Hill, Christopher Paul Newman, Luet Lok Wong, Tai-Chu Lau
-
Publication number: 20130303606Abstract: The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a compound including platinum (e.g., platinum(II) or platinum(IV)) compound comprising a beta-diketonate ligand.Type: ApplicationFiled: May 10, 2012Publication date: November 14, 2013Applicant: Massachusetts Institute of TechnologyInventors: Stephen J. Lippard, Justin J. Wilson
-
Publication number: 20130267709Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.Type: ApplicationFiled: June 3, 2013Publication date: October 10, 2013Inventors: David Thompson, Jeffrey W. Anthis
-
Patent number: 8524931Abstract: Precursor compositions useful for atomic layer deposition (ALD) and chemical vapor deposition (CVD) of strontium ruthenium oxide (SrRuO3) thin films, e.g., in the manufacture of microelectronic devices, as well as processes of making and using such precursors, and precursor supply systems containing such precursor compositions in packaged form. Cyclopentadienyl compounds of varied type are described, including cyclopentadienyl as well as non cyclopentadienyl ligands coordinated to ruthenium, strontium or barium central atoms. The precursors of the invention are useful for forming contacts for microelectronic memory device structures, and in a specific aspect for selectively coating copper metallization without deposition on associated dielectric, under deposition conditions in a forming gas ambient.Type: GrantFiled: March 12, 2007Date of Patent: September 3, 2013Assignee: Advanced Technology Materials, Inc.Inventors: Chongying Xu, Bryan C. Hendrix, Thomas M. Cameron, Jeffrey F. Roeder, Matthias Stender, Tianniu Chen
-
Patent number: 8519069Abstract: The present invention relates to a catalytic complex for olefin metathesis reactions, to a process for its preparation and to its use in olefin metathesis reactions, particularly in ring opening metathesis polymerisation (ROMP) reactions.Type: GrantFiled: July 7, 2010Date of Patent: August 27, 2013Assignee: RIMTEC CorporationInventor: Renata Drozdzak
-
Publication number: 20130209905Abstract: The present invention relates to a process for the production of hydrogen comprising contacting at least one complex of formula (I), wherein: X? is an anion; Y is N or CR6; M is selected from Ru, Os and Fe; each of A and B is independently a saturated, unsaturated or partially unsaturated carbocyclic ring; R5, R6 and R7 are each independently selected from H, NR24R25, C1-6-alkyl and C1-6-haloalkyl, or two or more of R5, R6 and R7 are linked, together with the carbons to which they are attached, to form a saturated or unsaturated carbocyclic group; R8-R25 are each independently selected from H, C1-6-alkyl, C1-6-haloalkyl and a linker group optionally attached to a solid support; with at least one substrate of formula (II), R1R2—NH—BH—R3R4 (II), wherein R1, R2, R3 and R4 are each independently selected from H, C1-20-alkyl, fluoro-substituted-C1-20-alkyl and C6-14-aryl, or any two of R1, R2, R3 and R4 are linked to form a C2-10-alkylene group, which together with the nitrogen and/or boron atoms to which they areType: ApplicationFiled: May 31, 2011Publication date: August 15, 2013Applicant: NOVAUCDInventors: Andrew Phillips, Dominique Schreiber
-
Patent number: 8507398Abstract: Catalysts for metathesis reactions, in particular for the metathesis of nitrile rubber, are provided.Type: GrantFiled: August 18, 2008Date of Patent: August 13, 2013Assignee: LANXESS Deutschland GmbHInventors: Ludek Meca, Lubica Triscikova, Heinz Berke, Kirsten Langfeld, Martin Schneider, Oskar Nuyken, Werner Obrecht
-
Patent number: 8507704Abstract: A formulation, comprising: a) at least one metal-ligand complex, wherein one or more ligands are selected from the group consisting of ?-diketonates, ?-ketoiminates, ?-ketoesterates, ?-diiminates, alkyls, carbonyls, alkyl carbonyls, cyclopentadienyls, pyrrolyls, alkoxides, amidinates, imidazolyls, and mixtures thereof; and the metal is selected from Group 2 to 16 elements of the Periodic Table of the Elements; and, b) at least one aminoether selected from the group consisting of R1R2NR3OR4NR5R6, R1OR4NR5R6, O(CH2CH2)2NR1, R1R2NR3N(CH2CH2)2O, R1R2NR3OR4N(CH2CH2)2O, O(CH2CH2)2NR1OR2N(CH2CH2)2O, and mixtures thereof, wherein R1-6 are independently selected from group consisting of C1-10 linear alkyl, C1-10 branched alkyl, C1-10 cyclic alkyl, C6-C10 aromatic, C1-10 alkylamine, C1-10 alkylaminoalkyl, C1-10 ether, C4-C10 cyclic ether, C4-C10 cyclic aminoether, and mixture thereof.Type: GrantFiled: August 30, 2010Date of Patent: August 13, 2013Assignee: Air Products and Chemicals, Inc.Inventors: Sergei Vladimirovich Ivanov, Xinjian Lei, Daniel P. Spence, John Anthony Thomas Norman, Laura M. Matz
-
Patent number: 8501977Abstract: A new platinum complex which has strong antitumor activity and has effect with smaller doses and a pharmaceutical composition containing the same are provided. A spiro[4,4]nonane-1,6-diamineplatinum(II) complex which is represented by a following general formula (A). (In the formula, X and Y are same or different, and X and Y represent halogen atoms respectively, or X and Y cooperatively represent a divalent residue which is described by a formula (Z).) The platinum complex has a strong antitumor activity and is efficacious as a therapeutic agent for malignant tumors.Type: GrantFiled: August 25, 2009Date of Patent: August 6, 2013Assignee: Unitech Co., Ltd.Inventors: Hisae Arai, Masaji Ohno, Hisao Kondo, Ikuko Arai
-
Patent number: 8481119Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.Type: GrantFiled: July 25, 2011Date of Patent: July 9, 2013Assignee: Applied Materials, Inc.Inventors: David Thompson, Jeffrey W. Anthis
-
Publication number: 20130158276Abstract: Provided is a catalyst for asymmetric reduction, which can be produced by a convenient and safe production method, has a strong catalytic activity, and has excellent stereoselectivity. The present invention relates to a ruthenium complex represented by the following formula (1): wherein R1 represents an alkyl group or the like; Y represents a hydrogen atom; X represents a halogen atom or the like; j and k each represent 0 or 1; R2 and R3 each represent an alkyl group or the like; R11 to R19 each represent a hydrogen atom, an alkyl group or the like; Z represents oxygen or sulfur; n1 represents 1 or 2; and n2 represents an integer from 1 to 3, a method for producing the ruthenium complex, a catalyst for asymmetric reduction formed from the ruthenium complex, and methods for selectively producing an optically active alcohol and an optically active amine using the catalyst for asymmetric reduction.Type: ApplicationFiled: June 17, 2011Publication date: June 20, 2013Applicant: TAKASAGO INTERNATIONAL CORPORATIONInventors: Taichiro Touge, Hideki Nara, Tomohiko Hakamada
-
Patent number: 8455672Abstract: Metal films are deposited with uniform thickness and excellent step coverage. Copper metal films were deposited on heated substrates by the reaction of alternating doses of copper(I) NN?-diispropylacetamidinate vapor and hydrogen gas. Cobalt metal films were deposited on heated substrates b the reaction of alternating doses of cobalt(II) bis(N,N?-diispropylacetamidinate) vapor and hydrogen gas. Nitrides and oxides of these metals can be formed by replacing the hydrogen with ammonia or water vapor, respectively. The films have very uniform thickness and excellent step coverage in narrow holes. Suitable applications include electrical interconnects in microelectronics and magnetoresistant layers in magnetic information storage devices.Type: GrantFiled: August 4, 2009Date of Patent: June 4, 2013Assignee: President and Fellows of HarvardInventors: Roy Gerald Gordon, Booyong S. Lim
-
Patent number: 8455543Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.Type: GrantFiled: June 10, 2011Date of Patent: June 4, 2013Assignee: University of South FloridaInventors: Heidi Kay, Jay W. Palmer, Joseph A. Stanko, Said M. Sebti
-
Publication number: 20130131368Abstract: The present invention is directed to a manufacturing process for 1,2-diamino-cyclohexane-platinum(II) complexes, specifically to a manufacturing process for oxaliplatin. The process is straightforward, economical and applicable to industrial production. It comprises the reaction of (DACH)PtCl2 with silver sulfate (Ag2SO4) and the subsequent reaction of the resulting Pt sulfate complex (DACH)Pt(aq)2SO4 with barium oxalate (BaC2O4) or an equimolar mixture of barium hydroxide and oxalic acid to yield oxaliplatin in high purity with a low silver and low nitrate content.Type: ApplicationFiled: June 22, 2010Publication date: May 23, 2013Inventor: Néstor Pablo Cid
-
Patent number: 8425921Abstract: The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.Type: GrantFiled: September 26, 2011Date of Patent: April 23, 2013Inventor: Heidi Kay
-
Patent number: 8426625Abstract: A compound of general formula (I): in which: R is selected from the group consisting of (C1-C25)alkyl, (C2-C25)alkenyl, aryl, (C7-C10)aralkyl; n and m are each independently an integer of two to eight; p is one or two; A is selected from the group consisting of —B—, —B—(CH2)r—B—, —B—(CH2)r—B—(CH2)z—B—, wherein r and z are an integer from 2 to 8, B is a —NR1— or —N(R2)2+1/pQ?p group, in which R1 is selected from hydrogen, (C1-C4)alkyl, (C1-C4)acyl, tert-butoxycarbonyl, and R2 is selected from hydrogen and (C1-C4)alkyl; Q?p is an anion selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R3COO? wherein R3 has the same meanings as R, independently from one another and R4—O—SO3? wherein R4 is (C2-C14)alkyl with the proviso that, when Q?p is selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R is not (C1-C4)alkyl.Type: GrantFiled: December 21, 2006Date of Patent: April 23, 2013Assignee: Cell Therapeutics, Inc.Inventors: Alberto Bernareggi, Mario Grugni, Giulio Mariotti, Ernesto Menta, Gianluca Pardi, Paolo Pavesi, Gabriella Pezzoni, Paolo Nicoli, Sergio De Munari
-
Publication number: 20130096090Abstract: The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.Type: ApplicationFiled: October 17, 2012Publication date: April 18, 2013Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.Inventor: Virginia Tech Intellectual Properties, Inc.
-
Patent number: 8404879Abstract: There are provided a ruthenium-diamine complex, and methods for selectively producing an optically active alcohol and an optically active amine, which are important as precursors for the synthesis of medicinal drugs and functional materials, using the ruthenium-diamine complex as a catalyst. The invention provides a ruthenium-diamine complex prepared by introducing a trisubstituted silyl group into an aromatic compound (arene) moiety that is coordinated with a ruthenium complex having an optically active diamine as a ligand, a catalyst for asymmetric reduction formed from the ruthenium-diamine complex, and a method for producing an optically active alcohol or an optically active amine using the catalyst.Type: GrantFiled: July 13, 2010Date of Patent: March 26, 2013Assignee: Takasago International CorporationInventors: Taichiro Touge, Hideki Nara
-
Publication number: 20130065864Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.Type: ApplicationFiled: May 20, 2011Publication date: March 14, 2013Applicant: UNIVERSITY OF WARWICKInventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
-
Patent number: 8394979Abstract: The present invention relates to a process for preparing cycloplatinated platinum(II) complexes, platinum(II) complexes prepared by this process and the use thereof for the treatment of tumor diseases and/or hemo blastoses.Type: GrantFiled: December 12, 2008Date of Patent: March 12, 2013Assignee: Rheinische-Westfalische Technische Hochschule AachenInventors: Ullrich Englert, Anca Beatrice Braun
-
Publication number: 20130053566Abstract: Cationic palladium catalysts comprising diamino carbene ligands, wherein the catalysts are of the formula [Pd(X)q(LBX)t(DC)]r+[Ym-]p or [Pd(X)q(LB)n(LBX)t(DC)]2a+[V?]u[Z2?]y, wherein DC is a diamino carbene ligand, X is an anionic ligand, LBX is a combined anionic and neutral ligand, and Y, V, and Z are non-coordinating anions. The compounds are useful in catalytic reactions, including cross-coupling reactions and hydroamination reactions. In particular, the catalysts are used in the following reactions: Suzuki-Miyaura coupling, Kumada coupling, Negishi coupling, Sonogashira coupling, Hartwig-Buchwald amination, and Heck-Mizoroki coupling.Type: ApplicationFiled: April 14, 2011Publication date: February 28, 2013Inventors: Kamaluddin Abdur-Rashid, Dino Amoroso, Chi-Wing Tsang, Wenli Jia
-
Patent number: 8383673Abstract: The invention relates to nitridoosmium complexes and methods of using these compounds as treatments for cancer.Type: GrantFiled: March 19, 2010Date of Patent: February 26, 2013Assignees: City University of Hong Kong, Versitech LimitedInventors: Tai Chu Lau, Yun Wah Lam, Wai Lun Man, Wen Xiu Ni, Chi-Ming Che
-
Patent number: 8362154Abstract: A novel process for the metathetic degradation of nitrile rubbers is provided which uses specific transition metal complex catalysts showing an increased activity.Type: GrantFiled: August 13, 2008Date of Patent: January 29, 2013Assignee: LANXESS Deutschland GmbHInventors: Christopher Ong, Werner Obrecht, Oskar Nuyken, Julia Maria Muller
-
Publication number: 20130023662Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.Type: ApplicationFiled: December 12, 2011Publication date: January 24, 2013Applicant: VANDA PHARMECEUTICALS INC.Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
-
Publication number: 20130018096Abstract: The present invention relates to the antitumor compound of formula (I) a process for its preparation and pharmaceutical compositions containing it.Type: ApplicationFiled: September 16, 2009Publication date: January 17, 2013Inventors: Sergio De Munari, Stefano Di Giovine, Mario Grugni, Paola Nicoli, Alessandro Paganelli, Gianluca Pardi, Gabriella Pezzoni
-
Publication number: 20130001535Abstract: The present invention provides a light-emitting organic platinum complex, a light-emitting material containing this complex, and a functional device containing this complex. The light-emitting organic platinum complex is represented by any one of the following structural formulae: where: Z represents either —(CH2)n— or —CH2(CH2OCH2)mCH2—, where n represents 7 to 14, and m represents 3 to 4; A represents either an optionally condensed aromatic hydrocarbon ring or an optionally condensed heteroaromatic ring; R is a substituent group for A and represents H (unless n of Z in the structural formula (1) is 7 to 13), a halogen, a C1-C6 alkyl group, a C1-C6 alkenyl group, a C1-C6 alkynyl group, a C1-C6 alkoxy group or the like.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicant: OSAKA UNIVERSITYInventors: Takeshi Naota, Naruyoshi Komiya, Minoru Okada
-
Patent number: 8338700Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the otherside of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.Type: GrantFiled: October 20, 2010Date of Patent: December 25, 2012Assignee: Nippon Kayaku Kabushiki KaishaInventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
-
Patent number: 8338629Abstract: Provided are an organometallic precursor, wherein a carboxyhydrazide compound is coordinated to a central metal, and a metal film or pattern using the precursor. By using the organometallic precursor, highly pure metal films or patterns can be obtained through a simple low-temperature process.Type: GrantFiled: March 6, 2009Date of Patent: December 25, 2012Assignee: Samsung Electronics Co., Ltd.Inventors: Young Hun Byun, Tatsiana Kuzniatsova, Hye Yeon Yang
-
Patent number: 8338701Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.Type: GrantFiled: October 20, 2010Date of Patent: December 25, 2012Assignee: Nippon Kayaku Kabushiki KaishaInventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
-
Patent number: 8318965Abstract: The present invention provides ruthenium compounds of the formula The compounds of the invention occur in the form of two isomers: trans and cis. The method of production of the compounds according to the invention is based on reacting an intermediate of formula (5) with a carbene complex of ruthenium. The invention also relates to the use of the compounds according to the invention for carrying out metathesis reactions.Type: GrantFiled: June 1, 2007Date of Patent: November 27, 2012Assignee: UMICORE AG & Co. KGInventors: Karol Grela, Michal Barbasiewicz, Anna Szadkowska
-
Publication number: 20120283505Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.Type: ApplicationFiled: July 18, 2012Publication date: November 8, 2012Inventors: Haruki Eguchi, Yoshihiro Ishikawa
-
Publication number: 20120252982Abstract: The present invention provides methods of depolymerizing and hydrogenating polymers using a transition metal catalyst represented by formula Ia or Ib: where the structural variables are defined herein.Type: ApplicationFiled: March 30, 2011Publication date: October 4, 2012Applicant: ZANNAN SCITECH CO., LTD.Inventor: Zheng-Yun James ZHAN
-
Patent number: 8273909Abstract: The present invention relates to a process for preparing palladium complexes. In particular, the present invention relates to a process in which ammoniacal complexes of palladium (hydrogen)carbonate are converted into complexes with oligoamine ligands.Type: GrantFiled: May 7, 2009Date of Patent: September 25, 2012Assignee: Umicore Galvanotechnik GmbHInventors: Sascha Berger, Franz Simon, Frank Oberst, Uwe Manz, Klaus Bronder, Bernd Weyhmueller
-
Patent number: 8247445Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.Type: GrantFiled: July 13, 2010Date of Patent: August 21, 2012Assignee: University of South FloridaInventors: Heidi Kay, Jay W. Palmer, Joseph A. Stanko
-
Patent number: 8242297Abstract: Metal-ligand combination initiators are provided which yield organometallic complexes capable of the polymerization of olefins to high molecular weight polymers. Additionally, these initiators also enable the copolymerization of olefins with functionalized comonomers. These organometallic complexes comprise of a late transition metal with a neutral chelating ligand that contains a Lewis basic functionality in conjugation with an electronically delocalized conduit extending from the metal to the functionality. This structural feature results in a highly active complex, which generates high molecular weight polymers with unique microstructures. Under particular conditions, the organometallic complexes provide for the living polymerization of monomers and comonomers.Type: GrantFiled: May 5, 2009Date of Patent: August 14, 2012Assignee: The Regents of the University of CaliforniaInventors: Jason D. Azoulay, Yanika Schneider, Guillermo C. Bazan
-
Publication number: 20120202764Abstract: Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12alkoxy, C1-12alkylamino, C1-12alkoxycarbonyl, C1-12alkylamido, arylamido, wherein the alkylene groupings in the given substituents can in turn be substituted by one or more of the following groups: hydroxy, oxy, carboxy, amino or amido; R3-R10, independently of each other, signify hydrogen; or NHR3R4 and NHR5R6, taken together, and/or NHR7R8 and NHR9R10, taken together, are a ligand (or ligands) containing one or several donor aliphatic or aromatic atoms of nitrogen and being in cis position on the metal atoms (M).Type: ApplicationFiled: July 12, 2010Publication date: August 9, 2012Applicant: "IVY PHARM" JSC.Inventors: Mark Borisovich Balazovsky, Viktor Georgievich Antonov, Alexandr Nikolaevich Belyaev, Alexei Vladimirovich Eremin
-
Patent number: 8232420Abstract: The present invention provides an organic metal compound, a ligand, an asymmetric catalyst, and a process for preparing optically-active alcohols using the asymmetric catalyst.Type: GrantFiled: April 12, 2010Date of Patent: July 31, 2012Assignee: Kanto Kagaku Kabushiki KaishaInventors: Masahito Watanabe, Junichi Hori
-
Publication number: 20120190874Abstract: Compounds comprising a metal complex having the structure [X—Y—Z-Mn+]p+.B are disclosed in which X is a histone deacetylase inhibitor, Mn+ is a DNA-binding heavy metal ion, Y is an aliphatic or aromatic spacer or is absent, and Z is a mono- or bi-dentate or chelating donor linker, or a bridging linker, P+ designates the charge on the complex ion, which may be positive, negative or absent and B is a counterion or is absent. The linker Z is labile and its metal complex X—Y—Z-Mn+ is capable of being hydrolysed in-vivo. The compounds find application in the treatment of cancer.Type: ApplicationFiled: July 13, 2010Publication date: July 26, 2012Applicant: ROYAL COLLEGE OF SURGEONS IN IRELANDInventors: Celine Josephine Marmion, Darren Griffith
-
Publication number: 20120187349Abstract: The present invention relates to compounds of the formula (I) and to the use thereof in electronic devices, in particular organic electroluminescent devices. Furthermore, the present invention relates to electronic devices comprising at least one compound according to the invention, preferably as emitter material or as charge-transport material.Type: ApplicationFiled: August 25, 2010Publication date: July 26, 2012Applicant: Merck Patent GmbHInventors: Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pflumm, Anja Gerhard
-
Publication number: 20120184014Abstract: Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.Type: ApplicationFiled: March 14, 2012Publication date: July 19, 2012Inventor: Pradip K. Mascharak
-
Patent number: 8211940Abstract: The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.Type: GrantFiled: October 9, 2009Date of Patent: July 3, 2012Assignee: Debiopharm S.A.Inventors: Houssam Ibrahim, Rolland-Yves Mauvernay
-
Publication number: 20120164230Abstract: Compounds and methods are disclosed in which a prodrug can be delivered in an elevated oxidative state to cells by means of graphitic nanoparticles to which the prodrug is attached by a hydrophilic polymer and which have been made soluble by a hydrophilic polymer, such as PEG. The graphitic nanoparticle may be a single walled carbon nanotube (SWNT). The prodrug may be a DNA-binding metal-based drug. Exemplified is a platinum(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], which is nearly nontoxic to testicular cancer cells, but displays a significantly enhanced cytotoxicity profile when attached to the surface of amine-functionalized soluble SWNTs. An amine functionality on the hydrophilic polymer may be used to link the prodrug.Type: ApplicationFiled: May 6, 2008Publication date: June 28, 2012Inventors: Rodney Feazell, Nozomi Nakayama-Ratchford, Hongjie Dai, Stephen J. Lippard
-
Publication number: 20120149906Abstract: Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N?-bis(3,5-di-t-butyl-salicylidene) and RuCl2(p-cymene)]2.Type: ApplicationFiled: December 12, 2011Publication date: June 14, 2012Applicant: VANDA PHARMECEUTICALS INC.Inventors: David E. Pereira, Wade Aumiller, Raymond Dagger
-
Publication number: 20120123142Abstract: The present invention relates to a process for hydrogenating a substrate comprising a carbon-heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): R1-10, A and Hal are as defined in the specification. The present invention also provides processes for the preparation of the complex of formula (I) and intermediates thereof.Type: ApplicationFiled: March 17, 2010Publication date: May 17, 2012Applicant: JOHNSON MATTHEY PUBLIC LIMITED COMPANYInventors: Alan Dyke, Damian Mark Grainger, Jonathan Alan Medlock, Hans Guenter Nedden, Jacques Jean Marie Le Paih, Stephen James Roseblade, Andreas Seger, Vilvanathan Sivakumar, Antonio Zanotti-Gerosa
-
Publication number: 20120107502Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.Type: ApplicationFiled: July 25, 2011Publication date: May 3, 2012Applicant: Applied Materials, Inc.Inventors: David Thompson, Jeffrey W. Anthis